Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Jung Won Shin

Jung Won is a reporter based in Seoul covering South Korea, most recently working for PharmAsia News. Her work covers corporate activities in the South Korean pharma/biotech sector as well as government policy and regulatory news. In her role, Jung Won focuses on R&D strategies, clinical development, licensing deals and other major corporate deals and activities in the country's pharma/biotech sector as well as major government measures or regulatory activities in the sector. 
Prior to joining Informa, Jung Won worked for Dow Jones Newswires in Seoul, covering stories in various industries and government. Outside of work, she likes to travel and spend time with her family and friends.

Set Alert for Articles By Jung Won Shin

Latest From Jung Won Shin

Korea May Adopt Further Cost-Containment Steps Under 'Moon Jae-In Care' – IQVIA

Korea is expected to feel the pressure to introduce more drug cost-containment measures amid rapidly rising National Health Insurance expenditures, IQVIA predicts. In particular, expenses associated with implementation of 'Moon Jae-in Care' could erode NHI financial surpluses in the short-medium term.
Policy Legislation

Robust Appetite For Biosolution IPO As OA Cell Therapy Nears Commercialization

Biosolution's IPO, which was priced at the high end of the range despite dampened biotech sentiment following the arrest of Nature Cell's CEO, is poised to help accelerate commercialization of the South Korean cell therapy company's osteoarthritis treatment CartiLife and the progress of other pipeline assets.

South Korea Financing

Nature Cell Mired In Uncertainty as CEO Arrested For Alleged Stock Price Manipulation

The Korean biotechs CEO and several other executives alleged involvement in stock price manipulation using false and exaggerated information on a pipeline stem cell therapy has damaged the credibility of its R&D efforts and shocked the domestic industry, although their fate remains to be determined after court trials.    

South Korea Legal Issues

Korea Outlines Device Regulatory Reforms And Other Steps To Foster Medtech

Amid repeated calls from industry that South Koreas medical device regulations must catch up with a rapidly changing industry, the country has unveiled measures to reform the rules and nurture the sector, including efforts to accelerate market entry of cutting-edge devices.

South Korea Regulation

Yuhan Licenses Out Degenerative Disc Therapy To Spine Despite Earlier Trial Failure

South Korean pharma firm licenses out to US venture Spine Biopharma novel peptide drug for degenerative disc disease YH14618, despite a Phase II failure and trial halt in 2016.

South Korea United States

Tech Transfer Roundup: UCSD Sees Many Benefits From Entrepreneurs In Residence Program

Asterias obtains IP estate related to ischemic stroke from University of California. Plus Apeiron, Qualigen, Biovaxys and AbbVie turn to academic partners for early-stage cancer assets.

Deals Research & Development
See All